Usenamine A: a potential therapeutic agent for rheumatoid arthritis and ankylosing spondylitis
Author Information
Author(s): Lee Yu Jeong, Li Zijun, Jang Hyun Hee, Kim Moon-Ju, Saravanakumar Kandasamy, Shim Seung Cheol, Cho Namki, Won Eun Jeong, Kim Tae-Jong
Primary Institution: Chonnam National University
Hypothesis
This study aimed to evaluate the potential anti-inflammatory effects of Usenamine A (UA) and its therapeutic effects on rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
Conclusion
Usenamine A has potential as a therapeutic agent that suppresses inflammatory cytokines and exhibits anti-inflammatory effects on arthritis.
Supporting Evidence
- Usenamine A did not affect cell viability in PBMCs from RA and AS patients.
- UA treatment significantly reduced the levels of inflammatory cytokines in PBMCs from RA and AS patients.
- In an arthritis mouse model, UA treatment resulted in significantly reduced clinical and histological scores.
Takeaway
Usenamine A might help people with arthritis by reducing inflammation in their bodies.
Methodology
The study involved molecular docking, treatment of peripheral blood mononuclear cells (PBMCs) from RA and AS patients with UA, and evaluation of its effects in an arthritis mouse model.
Limitations
Further research is necessary to elucidate the specific mechanisms of UA’s anti-inflammatory actions post-docking and more samples from RA and AS patients are needed.
Participant Demographics
{"RA":{"total":9,"age_mean":53.8,"male_percentage":33.3},"AS":{"total":9,"age_mean":43.4,"male_percentage":66.6}}
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website